Plasmapp Co. Ltd.
KKRX:4050003,550.00
KRW
-10.00
(-0.28%)
ISIN
KR7405000001
Return %
Stock
S&P 500
1Y
-57.23
14.39
3Y
-91.44
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Hyung-Min Kim
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Daejeon South Korea
- IPO Date
- Oct 21, 2022
- Website
- plasmapp.co.kr
- Similar Companies
- Business
- Plasmapp Co., Ltd. is a South Korea-based medical technology company that specializes in the development, manufacturing, and commercialization of advanced low-temperature plasma sterilization solutions and plasma bio-surface treatment systems for clinical applications. Founded in 2015 and headquartered in Daejeon, South Korea, the company serves healthcare providers across dental, orthopedic, ophthalmology, veterinary, and aesthetic surgical sectors globally. Plasmapp's core product and service portfolio comprises: low-temperature hydrogen peroxide vacuum plasma sterilizers marketed under the STERLINK brand (including STERLINK FPS, STERLINK 15sp, STERLINK mini, and STERLINK lite), which deliver rapid, low-heat instrument sterilization cycles; proprietary consumable sterilization packaging systems marketed under the Sterpack and Sterpack Plus lines, featuring direct-injection pouches and cassettes; vacuum plasma surface treatment devices marketed under the ACTILINK brand (including ACTILINK Reborn and ACTILINK Motion), designed to enhance the hydrophilicity, bio-compatibility, and osseointegration rates of dental implants, orthopedic screws, and biomaterials; and related consumables, biological indicators, chemical validation strips, and maintenance services. The company conducts business worldwide across North America, Europe, the Asia-Pacific region, Latin America, and the Middle East, supported by its overseas subsidiary, Plasmapp USA Inc. In recent developments, Plasmapp completed its public listing on the KOSDAQ market (KRX: 405000) and secured regulatory clearances, including United States Food and Drug Administration (FDA) 510(k) clearance for its STERLINK sterilization technology. The company has also expanded its global market reach by entering into long-term strategic supply, distribution, and original equipment manufacturer (OEM) partnerships with leading international dental and orthopedic implant corporations across the United States, Japan, and Europe, while broadening its research and commercial initiatives into regenerative medicine and specialized veterinary surgical care.